LT2315773T - Polipeptidai, polinukleotidai ir kompozicijos, skirti naudoti latentinės tuberkuliozės gydymui - Google Patents

Polipeptidai, polinukleotidai ir kompozicijos, skirti naudoti latentinės tuberkuliozės gydymui

Info

Publication number
LT2315773T
LT2315773T LTEP09781052.7T LT09781052T LT2315773T LT 2315773 T LT2315773 T LT 2315773T LT 09781052 T LT09781052 T LT 09781052T LT 2315773 T LT2315773 T LT 2315773T
Authority
LT
Lithuania
Prior art keywords
tubeculosis
polynucleotides
polypeptides
latent
compositions
Prior art date
Application number
LTEP09781052.7T
Other languages
English (en)
Lithuanian (lt)
Inventor
James Brown
Pascal Mettens
Dennis Murphy
Original Assignee
Glaxosmithkline Biologicals S.A.
Glaxo Group Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Biologicals S.A., Glaxo Group Limited filed Critical Glaxosmithkline Biologicals S.A.
Publication of LT2315773T publication Critical patent/LT2315773T/lt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/02Bacterial antigens
    • A61K39/04Mycobacterium, e.g. Mycobacterium tuberculosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00Preparations for testing in vivo
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • A61P31/06Antibacterial agents for tuberculosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/35Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Mycobacteriaceae (F)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
LTEP09781052.7T 2008-07-25 2009-07-24 Polipeptidai, polinukleotidai ir kompozicijos, skirti naudoti latentinės tuberkuliozės gydymui LT2315773T (lt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US8372008P 2008-07-25 2008-07-25
PCT/EP2009/059580 WO2010010177A1 (en) 2008-07-25 2009-07-24 Novel compositions and methods

Publications (1)

Publication Number Publication Date
LT2315773T true LT2315773T (lt) 2016-11-10

Family

ID=41217660

Family Applications (1)

Application Number Title Priority Date Filing Date
LTEP09781052.7T LT2315773T (lt) 2008-07-25 2009-07-24 Polipeptidai, polinukleotidai ir kompozicijos, skirti naudoti latentinės tuberkuliozės gydymui

Country Status (24)

Country Link
US (2) US20110117119A1 (OSRAM)
EP (1) EP2315773B1 (OSRAM)
JP (1) JP5873332B2 (OSRAM)
KR (1) KR20110044883A (OSRAM)
CN (1) CN102164952B (OSRAM)
AU (1) AU2009273130B2 (OSRAM)
BR (1) BRPI0916703A2 (OSRAM)
CA (1) CA2731499C (OSRAM)
CO (1) CO6341637A2 (OSRAM)
CY (1) CY1118200T1 (OSRAM)
DK (1) DK2315773T3 (OSRAM)
EA (1) EA024826B1 (OSRAM)
ES (1) ES2602430T3 (OSRAM)
HR (1) HRP20161458T1 (OSRAM)
HU (1) HUE031044T2 (OSRAM)
IL (1) IL210559A0 (OSRAM)
LT (1) LT2315773T (OSRAM)
MX (1) MX2011000983A (OSRAM)
PL (1) PL2315773T3 (OSRAM)
PT (1) PT2315773T (OSRAM)
SG (1) SG192456A1 (OSRAM)
SI (1) SI2315773T1 (OSRAM)
UA (1) UA107330C2 (OSRAM)
WO (1) WO2010010177A1 (OSRAM)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2348475A1 (en) * 1998-11-04 2000-05-11 Isis Innovation Limited Tuberculosis diagnostic test
SI2315834T1 (sl) 2008-07-25 2018-09-28 Glaxosmithkline Biologicals S.A. Tuberkulozni Rv2386c protein, sestavki in njegove uporabe
NO2315597T3 (OSRAM) * 2008-07-25 2018-01-20
EP2156945A1 (en) 2008-08-13 2010-02-24 Novelis Inc. Clad automotive sheet product
US9074001B2 (en) 2009-04-24 2015-07-07 Statens Serum Institut Tuberculosis TB vaccine to prevent reactivation
WO2011092253A1 (en) 2010-01-27 2011-08-04 Glaxosmithkline Biologicals S.A. Modified tuberculosis antigens
CN105814573B (zh) 2013-09-27 2019-03-29 科德克希思公司 基于定向进化的方法、装置及系统
EP3418929B1 (en) 2013-09-27 2020-12-09 Codexis, Inc. Automated screening of enzyme variants
GB201405921D0 (en) * 2014-04-02 2014-05-14 Glaxosmithkline Biolog Sa Novel methods for inducing an immune response
CN106546737A (zh) * 2016-10-24 2017-03-29 广州迪澳医疗科技有限公司 一种体外检测活动性结核的方法
GB201621686D0 (en) 2016-12-20 2017-02-01 Glaxosmithkline Biologicals Sa Novel methods for inducing an immune response
GB201707700D0 (en) 2017-05-12 2017-06-28 Glaxosmithkline Biologicals Sa Dried composition
GB2600652B (en) 2017-05-30 2022-11-02 Glaxosmithkline Biologicals Sa Novel compositions
CN111670044A (zh) 2017-12-01 2020-09-15 葛兰素史密丝克莱恩生物有限公司 皂苷纯化
EA202192738A1 (ru) 2019-04-12 2022-03-17 С4 Терапьютикс, Инк. Трициклические соединения, обеспечивающие разрушение белка ikaros и белка aiolos
CN114080393A (zh) 2019-06-05 2022-02-22 葛兰素史克生物有限公司 皂苷纯化
CN115073612B (zh) * 2022-06-22 2024-09-27 宁夏大学 一种结核分枝杆菌Zera-71cA蛋白纳米颗粒、制备方法及其用途
GB202318595D0 (en) * 2023-12-05 2024-01-17 Sec Dep For Environment Food And Rural Affairs Acting Through Animal And Plant Health Agency Diagnostic proteins and reagents

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6613881B1 (en) * 1997-05-20 2003-09-02 Corixa Corporation Compounds for immunotherapy and diagnosis of tuberculosis and methods of their use
KR100692227B1 (ko) * 1998-04-07 2007-03-09 코릭사 코포레이션 마이코박테리움 튜베르쿨로시스 항원의 융합 단백질 및이의 용도
AU2001241738A1 (en) * 2000-02-25 2001-09-03 Corixa Corporation Compounds and methods for diagnosis and immunotherapy of tuberculosis
EP1542732B1 (en) * 2000-06-20 2009-09-16 Corixa Corporation Fusion proteins of mycobacterium tuberculosis
WO2002054072A2 (en) * 2001-01-08 2002-07-11 Isis Innovation Limited Assay to determine efficacy of treatment for mycobacterial infection
US7538206B2 (en) * 2001-02-22 2009-05-26 Institut Pasteur Comparative mycobacterial geneomics as a tool for identifying targets for the diagnosis, prophylaxis or treatment of mycobacterioses
US20030236393A1 (en) * 2002-03-22 2003-12-25 United States Of America Dept Of Vetrans Affairs Virulence genes of M. marinum and M. tuberculosis
EP1781313A4 (en) * 2004-06-17 2009-08-26 Beckman Coulter Inc MYCOBACTERIUM TUBERCULOSIS EPITOPES AND METHODS OF USE
ES2381492T3 (es) 2005-04-29 2012-05-28 Glaxosmithkline Biologicals Sa Procedimiento de prevención o tratamiento de infección por M. tuberculosis
EP2380589A3 (en) * 2005-06-23 2012-09-12 Statens Serum Institut Improved tuberculosis vaccines
WO2008007942A1 (en) * 2006-07-10 2008-01-17 Het Nederlands Kanker Instituut Means and methods for manipulating sequential phagolysomal-cytosolic translocation of mycobacteria, and uses thereof
WO2008140478A2 (en) * 2006-11-01 2008-11-20 Immport Therapeutics, Inc. Compositions and methods for immunodominant antigens
US9074001B2 (en) * 2009-04-24 2015-07-07 Statens Serum Institut Tuberculosis TB vaccine to prevent reactivation
WO2011092253A1 (en) 2010-01-27 2011-08-04 Glaxosmithkline Biologicals S.A. Modified tuberculosis antigens

Also Published As

Publication number Publication date
CA2731499C (en) 2017-01-10
MX2011000983A (es) 2011-03-02
PT2315773T (pt) 2016-11-23
EP2315773B1 (en) 2016-08-24
CN102164952B (zh) 2016-05-25
UA107330C2 (uk) 2014-12-25
CO6341637A2 (es) 2011-11-21
WO2010010177A1 (en) 2010-01-28
AU2009273130A1 (en) 2010-01-28
US20110117119A1 (en) 2011-05-19
DK2315773T3 (en) 2016-12-12
EP2315773A1 (en) 2011-05-04
EA024826B1 (ru) 2016-10-31
EA201100072A1 (ru) 2011-10-31
ES2602430T3 (es) 2017-02-21
JP5873332B2 (ja) 2016-03-01
BRPI0916703A2 (pt) 2019-12-24
US20140178423A1 (en) 2014-06-26
SI2315773T1 (sl) 2016-12-30
CA2731499A1 (en) 2010-01-28
CY1118200T1 (el) 2017-06-28
KR20110044883A (ko) 2011-05-02
SG192456A1 (en) 2013-08-30
US9795663B2 (en) 2017-10-24
IL210559A0 (en) 2011-03-31
AU2009273130B2 (en) 2014-10-16
HUE031044T2 (en) 2017-06-28
JP2011528895A (ja) 2011-12-01
CN102164952A (zh) 2011-08-24
PL2315773T3 (pl) 2017-07-31
HRP20161458T1 (hr) 2016-12-16

Similar Documents

Publication Publication Date Title
SI2315773T1 (sl) Polipeptidi, polinukleotidi in sestavki za uporabo pri zdravljenju latentne tuberkuloze
AP2965A (en) Therapeutic compositions and the use thereof
AP2490A (en) Therapeutic compositions and the use thereof
PL1975226T3 (pl) Płynna kompozycja do obróbki
EP2314278A4 (en) HAIR TREATMENT COMPOSITION
IL213365A (en) Imidazopyrazine and their pharmaceutical preparations
IL207096A0 (en) Modified leptin polypeptides and their uses
PT2101731T (pt) Endoxifeno para utilização no tratamento de cancro
IL195152A (en) Compounds for use in treating diseases of cell culture
PL2190405T3 (pl) Kompozycje do traktowania włosów
IL215592A (en) Compounds, preparations containing them and their uses in the treatment or prevention of conditions in the eyes
GB0719202D0 (en) Compositions and methods for the skin and hair
PL2209458T3 (pl) Kompozycje do traktowania skóry
PL2066408T3 (pl) Kompozycja na bazie ksantoksyliny i jej zastosowanie w kosmetyce
MX303262B (es) Composicion de locion para uso personal.
ZA200905427B (en) Rasp and cover
PL2012805T3 (pl) Kompozycja lecznicza i jej zastosowanie
GB0822486D0 (en) Compounds for use in the treatment of pain
GB0714500D0 (en) composition and treatment
GB2461611B (en) Composition and use thereof
ZA200807154B (en) Liquid treatment composition
ZA201000469B (en) Therapeutic compositions and the use thereof
GB0622040D0 (en) Skin treatment composition
GB0808877D0 (en) Composition and use thereof
GB0810409D0 (en) Composition and use thereof